Wedbush reaffirmed their outperform rating on shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) in a research report released on Wednesday morning, RTT News reports. Wedbush currently has a $5.00 price objective on the stock, up from their previous price objective of $4.00. Separately, Needham & Company LLC reissued a buy rating and issued a […]
G1 Therapeutics (NASDAQ:GTHX – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06, Zacks reports. G1 Therapeutics had a negative return on equity of 132.03% and a negative net margin of 90.82%. The firm had […]
G1 Therapeutics (NASDAQ:GTHX – Get Free Report) is scheduled to post its 12/31/2023 quarterly earnings results before the market opens on Wednesday, February 28th. Analysts expect G1 Therapeutics to post earnings of ($0.27) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link. […]
G1 Therapeutics (NASDAQ:GTHX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They currently have a $14.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 243.14% from the company’s […]
Needham & Company LLC reiterated their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $14.00 price objective on the stock. A number of other analysts have also recently commented on the stock. Wedbush reaffirmed an outperform rating and set […]